Charles Schwab Investment Management Inc. Purchases 4,115 Shares of Sera Prognostics, Inc. (NASDAQ:SERA)

Charles Schwab Investment Management Inc. grew its position in shares of Sera Prognostics, Inc. (NASDAQ:SERA) by 5.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 81,228 shares of the company’s stock after acquiring an additional 4,115 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Sera Prognostics were worth $661,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Jane Street Group LLC lifted its stake in Sera Prognostics by 24.8% in the third quarter. Jane Street Group LLC now owns 14,225 shares of the company’s stock worth $111,000 after acquiring an additional 2,826 shares during the period. Pallas Capital Advisors LLC bought a new position in Sera Prognostics in the 4th quarter worth $113,000. MetLife Investment Management LLC lifted its position in shares of Sera Prognostics by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 17,254 shares of the company’s stock worth $135,000 after purchasing an additional 9,722 shares during the period. Rhumbline Advisers boosted its stake in shares of Sera Prognostics by 10.6% during the 4th quarter. Rhumbline Advisers now owns 36,101 shares of the company’s stock valued at $294,000 after purchasing an additional 3,468 shares in the last quarter. Finally, Barclays PLC boosted its stake in shares of Sera Prognostics by 321.6% during the 3rd quarter. Barclays PLC now owns 39,450 shares of the company’s stock valued at $308,000 after purchasing an additional 30,093 shares in the last quarter. 54.64% of the stock is owned by institutional investors.

Sera Prognostics Price Performance

SERA stock opened at $3.68 on Tuesday. Sera Prognostics, Inc. has a 1 year low of $3.33 and a 1 year high of $12.36. The firm has a 50-day moving average of $4.60 and a 200 day moving average of $6.40. The company has a market cap of $138.60 million, a P/E ratio of -3.72 and a beta of 0.89.

Sera Prognostics (NASDAQ:SERA) last announced its earnings results on Wednesday, March 19th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.02). The firm had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.01 million. During the same period in the prior year, the company earned ($0.25) earnings per share. On average, equities research analysts expect that Sera Prognostics, Inc. will post -0.96 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Joshua Phillips sold 12,163 shares of Sera Prognostics stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $6.39, for a total transaction of $77,721.57. Following the completion of the transaction, the director now directly owns 2 shares in the company, valued at approximately $12.78. This trade represents a 99.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Robert Gardner Harrison sold 14,209 shares of the company’s stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $7.39, for a total value of $105,004.51. Following the completion of the sale, the insider now owns 116,837 shares in the company, valued at $863,425.43. The trade was a 10.84 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 69,877 shares of company stock worth $480,677. 15.80% of the stock is owned by corporate insiders.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.